[HTML][HTML] Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non …
LJ Hung, PC Hsu, CT Yang, CHS Kuo… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Background: In real-world practice, most patients with lung cancer are diagnosed when they
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors
Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic
treatment options, improving patients' outcome. This benefit is not only achieved in the …
treatment options, improving patients' outcome. This benefit is not only achieved in the …
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd …
PC Hsu, CY Huang, YC Lin, SH Lee, LC Chiu… - Frontiers in …, 2023 - frontiersin.org
Introduction The clinical outcomes of sequential treatment of advanced epidermal growth
factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line …
factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line …
Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non …
LC Chiu, PC Hsu, CC Wang, HW Ko, SCH Kuo… - Thoracic …, 2024 - Wiley Online Library
Background This study aimed to investigate the factors associated with prolonged
progression‐free survival (PFS)(> 36 months) of advanced non‐small cell lung cancer …
progression‐free survival (PFS)(> 36 months) of advanced non‐small cell lung cancer …
[HTML][HTML] Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study …
Y Wang, Y Zhang, N Ren, F Li, L Lu, X Zhao… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Objectives The safety and feasibility of repeat biopsy after systemic treatment for non-small
cell lung cancer have received extensive attention in recent years. The purpose of this …
cell lung cancer have received extensive attention in recent years. The purpose of this …
Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine …
YJ Tang, JWC Chang, CY Huang… - Journal of Cancer …, 2024 - journals.lww.com
Background: Several deletion and insertion subtypes occur in exon 19 of the epidermal
growth factor receptor (EGFR) gene, collectively called exon 19 deletions (del19), and are …
growth factor receptor (EGFR) gene, collectively called exon 19 deletions (del19), and are …
Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S …
ZW Chen, G Lin, HJ Shih, CE Wu - International Journal of Molecular …, 2022 - mdpi.com
Epidermal growth factor receptor (EGFR) triple mutations with exon 19 deletion (del19),
T790M, and cis-C797S (del19/T790M/cis-C797S mutations) frequently occur in patients with …
T790M, and cis-C797S (del19/T790M/cis-C797S mutations) frequently occur in patients with …